KR100201585B1 - Vasodilator composition - Google Patents

Abstract

The present invention relates to a vasodilator composition comprising ginsenoside Rg ₃ and / or Rg ₅ as one of the components of ginseng as an active ingredient. Ginsenosides Rg ₃ and Rg ₅ , the active ingredients of the composition according to the present invention exhibits vascular relaxation in an endothelial manner, and unlike general saponin components, do not destroy endothelial cells and thus can be used without side effects such as hemolytic action or fish toxicity. It is a safe medicinal ingredient. Ginsenosides Rg ₃ and Rg ₅ are rarely present in ginseng plants such as ginseng and white ginseng, and are present only in trace amounts in red ginseng.The contents of ginseng plants are heated by heating the ginseng plants at a high temperature of 110 to 180 ° C. for 0.5 to 20 hours This increases significantly.

Description

Vasodilator composition

Figure 1 shows the vasorelaxant effect of ginsenoside Rg ₃ administered alone in the presence of endothelial cells. When endothelium was removed and administered (-○-), when Rg ₃ was co-administered with 10 ^-6 M of methylene blue (MB) in the presence of endothelium (-△-) and 10 ^-6 M of L- When combined with nitroarginine (L-NLA) (- This graph is compared with the vasorelaxant effect of-).

Figure 2 is when the processed panaxanthol-based saponin fraction prepared in Example 7 was administered in the presence of endothelial (- -) And a graph showing a comparison of the vasorelaxant effect when the endothelium was removed and administered.

FIG. 3 is a graph showing the results of cytotoxicity test of ginsenoside Rg ₃ and dimethyl sulfoxide (DMSO) used for HUVEC cells when cultured with DMSO (-○-) and ginsenoside Rg _3. Was cultured by adding a solution dissolved in DMSO (- It is a graph comparing the survival rate of the cells of-).

FIG. 4 shows the vasorelaxant effect (-○-) when ginsenoside Rg ₅ was administered alone in the presence of endothelial cells. When Rg ₅ was coadministered with ^10-6 M of methylene blue (MB) in the presence of endothelial cells (-) -) And ^10-6 M L-nitroarginine (L-NLA) when combined with (-Δ-) vascular relaxation effect compared with the graph shown.

FIG. 5 is a graph showing the results of cytotoxicity test of ginsenoside Rg ₅ and dimethyl sulfoxide (DMSO) used as a solvent for HUVEC cells. And cultured by adding a solution of ginsenoside Rg ₅ dissolved in DMSO (- It is a graph comparing the survival rate of the cells of-).

The present invention relates to a vasodilator composition containing a specific active ingredient of ginseng as an active ingredient. More specifically, the present invention relates to a vasodilator composition containing ginsenoside Rg ₃ and / or Rg ₅ as one of the saponin-based components of ginseng as an active ingredient.

Ginseng has been widely used as the most representative nourishing tonic from whales, and recently, many researches on its ingredients and efficacy have been reported, and the mysterious effects of it are being illuminated by modern science.

In general, ginseng is used in the form of red ginseng, which is produced by heat-treating white ginseng or ginseng dried at room temperature as it is grown and harvested. Among them, red ginseng is known to be much stronger than white ginseng. Recently, research on specific components of red ginseng has been actively conducted. These ingredients are produced during the manufacturing process of red ginseng and are evaluated as a component that can explain the excellent efficacy of red ginseng.

Therefore, the present inventors have studied a means to enhance the efficacy of ginseng by increasing the specific components of red ginseng, and as a result, when the ginseng is heated and treated at a high temperature of 110 to 180 ° C. for 0.5 to 20 hours, the existing ginseng or It was confirmed that processed ginseng with much enhanced efficacy than white ginseng or red ginseng. In the process of separating the various components present in such processed ginseng and verifying its efficacy, the present inventors have no ginsenoside Rg ₃ and Rg, which have not been known so far in the white ginseng or red ginseng. _It was confirmed that ₅ exhibits an excellent vasorelaxant effect and completed the present invention.

Accordingly, the present invention relates to vasodilator compositions containing ginsenosides Rg ₃ and / or Rg ₅ as active ingredients.

Ginsenosides Rg ₃ and Rg ₅ used as the active ingredient in the composition according to the present invention is a saponin compound having the structure as follows. In the present invention, pure ginsenosides Rg ₃ and / or Rg ₅ are used, or ginsenosides. Processed ginseng or extracts thereof enhanced with the side Rg ₃ and / or Rg ₅ components may also be used.

Rg ₃ and / or the content of Rg ₅ of the extract when using the processed ginseng extract containing Rg ₃ and / or Rg ₅ in the composition according to the invention as the active component is at least 10% (w / w) This is preferable because when the content of Rg ₃ and / or Rg ₅ is less than 10%, too much ginseng extract must be used in order to sufficiently obtain the desired vasorelaxant effect.

Ginseng extract with enhanced ginsenoside Rg ₃ and / or Rg ₅ , or ginsenoside Rg ₃ and / or Rg ₅ in the composition according to the present invention is processed ginseng obtained by heating ginseng or ginseng leaves at a high temperature, Alternatively, it can be obtained from the acid hydrolyzate of ginseng extract.

Ginseng extracts fortified with ginsenosides Rg ₃ and / or Rg ₅ include Panax plants containing ginseng saponins, such as Panax ginseng, Panax notoginseng, Panax quinquefolium ), Panax japonicus, or the like, or the leaves of these plants, tissue cultures of these plants, or extracts from water or lower alcohols, are heated at a temperature of 110 to 180 ° C. for 0.5 to 20 hours. The obtained ginseng is extracted with water or a suitable organic solvent such as methanol, ethanol or a mixed solvent thereof, and then the extract is concentrated under reduced pressure and suspended in water, followed by a nonpolar organic solvent such as hexane, ether, After extracting with dichloromethane, chloroform, ethyl acetate or a mixed solvent thereof, the remaining aqueous layer is extracted with a polar organic solvent such as butanol and extracted. By Mato calligraphy it is possible to obtain a fraction to obtain a fraction containing Rg or Rg ₃ or ₅ containing Rg Rg ₃ and ₅ at the same time. At this time, repeated chromatography can increase the content of ginsenosides Rg ₃ or Rg ₅ , and the fractions with higher contents can be added to an appropriate solvent system, such as water, lower alcohol, lower ketone, chloroform or a mixed solvent thereof. Crystallization in the same solvent system can yield pure ginsenosides Rg ₃ or Rg ₅ . In this method, the ginsenoside of ginsenoside Ra, Rb ₁ , Rb ₂ , Rc, and Rd, which is a panaxidiol-based saponin present in ginseng, falls off in the process of heat-treating ginseng. Rg ₃ is generated, Rg ₃ continues to dehydrate and a double bond is generated at position 20 to generate Rg ₅ . In some cases, the heat treatment step and the organic solvent extraction step may be alternately performed, or the acid may be heated under mild conditions, for example, at 30 to 100 ° C., preferably at 70 ° C., instead of being heated at a high temperature. The same result can be obtained by performing acid treatment with dilute mineral acid such as hydrochloric acid, nitric acid, perchloric acid, or lower organic acid such as acetic acid, tartaric acid, oxalic acid.

In the above process, instead of ginseng, known compounds such as ginsenosides Ra, Rb ₁ , Rb ₂ , Rc, and Rd or fractions thereof may be directly heated or acid hydrolyzed in the same manner as described above. You can get the result.

On the other hand, when preparing a ginseng extract containing Rg ₃ and / or Rg ₅ , before heating the ginseng, using an organic solvent, for example, an alcohol solvent such as methanol, ethanol, butanol, ether solvent, or a mixed solvent thereof Extraction of undesired panaxantholol saponin components to obtain a fraction containing a high concentration of panaxadiol-based saponin components and heat-treated in the same manner as mentioned above to a large amount of Rg ₃ and / or Rg ₅ A processed panaxadiol-based saponin fraction containing no unwanted panaxtriol-based chaponin components may be obtained and used as a processed ginseng extract containing Rg ₃ and / or Rg ₅ .

The composition containing ginsenoside Rg ₃ and / or Rg ₅ as an active ingredient according to the present invention has a strong vasorelaxant effect, hypertension, arteriosclerosis, blood circulation disorders due to circulatory disorders, diabetes, sexual dysfunction, memory disorders It can be usefully used as a prophylactic and therapeutic agent for such diseases. When used clinically for this purpose, the composition of the present invention may be combined with a conventional carrier in the pharmaceutical field to provide oral administration of conventional agents in the pharmaceutical field, such as tablets, capsules, troches, solutions, suspensions, and the like. Topical formulations, such as injectable preparations, ointments, creams, liquids, etc., in the form of preparations for injection, injectable solutions or suspensions, or ready-to-use injectable dry powders which can be prepared by injection with distilled water for injection. It can be formulated into a variety of formulations, such as.

Carriers that can be used in the compositions of the present invention are conventional in the pharmaceutical field, for example in the case of oral preparations, binders, suspending agents, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, pigments And fragrances. In the case of injectables, there are preservatives, analgesics, solubilizers, stabilizers, and the like, and in the case of topical administration, there are bases, excipients, lubricants, and preservatives. The pharmaceutical preparations thus prepared can be administered orally or parenterally, eg, intravenously, subcutaneously, intraperitoneally, or topically. In addition, in order to prevent the decomposition of the drug by gastric acid during oral administration, an antacid may be used in combination, or a solid dosage form for oral administration such as tablets may be formulated into a formulation coated with enteric skin.

The dose of ginsenosides Rg ₃ and / or Rg _{5 to} the human body according to the present invention depends on the absorption rate, inactivation rate and excretion rate of the active ingredient in the body, the age, sex and condition of the patient, the severity of the disease to be treated, and the like. Although appropriately selected, generally an adult is allowed to receive an amount of 5-500 mg, preferably 10-200 mg per day. Therefore, when preparing the composition of the present invention in unit dosage form, each unit dosage form is 5 to 500 mg, preferably 10 to 200 mg of ginsenoside Rg ₃ and / or Rg ₅ in consideration of the above-mentioned effective dose range. It can be formulated to contain. The unit dosage form thus formulated may be divided into several times, preferably 1 to 6 times, using specialized dosing methods or according to the needs of the individual who monitors or observes the administration of the drug as needed and according to the needs of the individual. May be administered.

Ginsenosides Rg ₃ and Rg ₅ of the active ingredient of the composition according to the present invention exhibits the effect of relaxing the blood vessels without damaging the vascular endothelial as demonstrated by the experimental results described later, so side effects such as hemolysis or fish toxicity In addition, it is not acutely toxic to experimental animals and can be used safely.

The present invention is explained in more detail by the following examples and experimental examples, but the present invention is not limited in any way by these.

Example 1

Preparation of Ginseng Extract Containing Ginsenoside Rg ₃

100 g of fresh ginseng was put in a sealed container and heated at 130 ° C. for 2 hours. The processed ginseng was extracted with 200 ml of methanol to obtain a methanol extract, and methanol was evaporated and removed. The remaining residue was suspended in 100 ml of water, extracted three times with 100 ml of ether, and the remaining aqueous layer was extracted three times with 100 ml of saturated butanol. A butanol extract containing saponin was obtained. The butanol extract was dried and chromatographed on a silica gel column using a mixed solvent of ethyl acetate / methanol / water (20: 1: 1) as eluent to obtain 1.5 g of a fraction containing 60% of the desired ginsenoside Rg ₃ . .

Example 2

Preparation of Ginseng Extract Containing Ginsenoside Rg ₅

In the same manner as in Example 1, 1.0 g of a fraction containing 50% of the desired ginsenoside Rg ₅ was obtained.

Example 3

Preparation of Ginseng Extract Containing Ginsenoside Rg ₃

Methanol 2 was added to 1 kg of dried ginseng, refluxed in a water bath for 4 hours, extracted, and the ginseng extract obtained by filtration was dried under reduced pressure. The obtained syrup-like ginseng extract was put into an autoclave and heated at 120 ° C. for 4 hours. The heat treated ginseng extract was chromatographed on a silica gel column in the same manner as in Example 1 to obtain 20 g of a fraction containing 65% of the desired ginsenoside Rg ₃ .

Example 4

Preparation of Ginseng Extract Containing Ginsenoside Rg ₅

In the same manner as in Example 3, 10 g of a fraction containing 60% of the desired ginsenoside Rg ₅ was obtained.

Example 5

Preparation of Ginseng Extract Containing Ginsenoside Rg ₃

2 g of methanol was added to 1 kg of white ginseng, reflux extracted for 4 hours in a water bath, and the ginseng extract obtained by filtration was dried under reduced pressure. The ginseng extract of the obtained syrup was acid-treated by well-known crime prevention (Refer .: Journal of Pharmaceutical Sciences, Vol. 35, No. 432-437 (1991)). That is, the ginseng extract was dissolved in 1 L of a water / acetic acid (1: 1) mixed solvent, heated with stirring at 70 ° C. for 2 hours, and then the solvent was removed. Chromatography on the separation gave 20 g of a fraction containing 72% of the desired ginsenoside Rg ₃ .

Example 6

Preparation of Ginseng Extract Containing Ginsenoside Rg ₅

In the same manner as in Example 5, 10 g of a fraction containing 60% of the desired ginsenoside Rg ₅ was obtained.

Example 7

Preparation of Processed Panaxanadiol Saponin Fraction

1 kg of ginseng was extracted with 200 ml of methanol to obtain a methanol extract, and methanol was evaporated and removed. The remaining residue was suspended in 100 ml of water and extracted three times with 100 ml of ether. The remaining aqueous layer was extracted three times with ethyl acetate: butanol = 10: 1 mixed solvent, and the remaining aqueous layer was extracted three times with 100 ml of butanol again to obtain a panaxadiol-based saponin fraction. This panaxanadiol-based saponin fraction was heat-treated at 130 ° C. for 3 hours in the same manner as in Example 1 to obtain about 40 g of a processed panaxadiol-based saponin fraction.

Example 8

Preparation of Ginsenoside Rg ₃

1 g of the ginsenoside Rg _3- containing fraction obtained in Example 3 was chromatographed on a silica gel column in the same manner as in Example 1, using a mixed solvent of ethyl acetate / methanol / water (20: 1: 1) as the eluent. Was repeated to obtain 500 mg of the fraction containing 92% of the desired ginsenoside Rg ₃ . The obtained ginsenoside Rg ₃ containing fractions were recrystallized from methanol and ethyl acetate mixed solvent to obtain about 400 mg of the desired ginsenoside Rg ₃ .

The obtained ginsenoside Rg ₃ is ¹³ consistent with that known in Japanese Pharmaceutical Journal, 103 (6), 612-622 (1983) or Pharmacy Journal No. 35, No. 5, 432-437 (1991). C-NMR spectrum and mass spectrum are shown. That is, about 10 mg of the obtained ginsenoside Rg ₃ was dissolved in 600 µl of pyridine-d ₅ (99.5%), and the carbon nuclear magnetic resonance spectrum was measured to show a characteristic peak of Rg ₃ . In addition, the mass spectrum (FAB +) of ginsenoside Rg ₃ shows a molecular ion peak of 785 ([M + H] ⁺ ) or 807 ([M + Na] ⁺ ).

Example 9

Preparation of Ginsenoside Rg ₅

1 g of the ginsenoside Rg _5- containing fraction obtained in Example 4 was obtained in the same manner as in Example 8 to obtain 200 mg of the fraction containing about 90% of Rg ₅ , and the obtained ginsenoside Rg ₅ -containing fraction was methanol. And recrystallization from an ethyl acetate mixed solvent to obtain about 150 mg of the desired ginsenoside Rg ₅ .

The obtained ginsenoside Rg ₅ has the following physicochemical characteristics.

MS (FAB +, m / z): 789 ([M + NA] ⁺ ), 805 ([M + K] ⁺ )

¹³ C-NMR (ppm, pyridine-d ₅ ): δ 13.0, 16.0, 16.5, 16.6, 17.0, 17.8, 18.5, 25.8, 26.7, 27.0, 27.4, 28.1, 32.3, 32.6, 35.3, 37.0, 39.2, 39.7, 40.2, 50.5, 50.9, 51.2, 56.4, 62.6, 62.8, 71.4, 72.4, 72.6, 77.2, 77.9, 78.1, 78.3, 78.3, 83.5, 88.9, 105.2, 106.1, 123.5, 124.6, 131.2, 140.2

Experimental Example 1

Vasorelaxation of Ginsenosides Rg ₃ and Rg ₅

Endothelial vessels play a very important role in maintaining homeostasis, such as regulating blood flow and blood vessel tension and inhibiting platelet aggregation. In particular, the endothelium of blood vessels is called

elium-derived relaxing factor, or nitric oxide (NO), which acts on vascular smooth muscle to activate soluble guanylate cyclase and increase cyclic GMP in tissues to relax blood vessels It is known to make. When endothelial function is impaired by circulatory diseases such as hypertension and hypercholesterolemia, the release of nitric oxide is reduced and normal vascular control function is lost. However, most saponin components were not desirable because they showed serious side effects such as hemolysis or fish toxicity because they showed vascular relaxation while destroying endothelial cells. Therefore, there is a need for a component that exhibits a relaxing effect on blood vessels without damaging the endothelium.

The present inventors confirmed that ginsenosides Rg ₃ and Rg ₅ exhibit potent endothelial-dependent vasorelaxation unlike conventional saponin components, which is demonstrated experimentally below.

1. Experiment Method

Rapid extraction of thoracic aorta from Sprague-Dowley (SD) rats of 300-400 g was performed with Krebs-Ringer-Sodium bicarbonate solution (Control, NaCl 118.3; KCl 4.7; MgSO ₄ 1.2; KH ₂ PO _4). 1.2; CaCl ₂ 2.5; NaHCO ₃ 25; CaEDTA 0.016; glucose 11.1 mM). Fat and connective tissue around blood and blood vessels were removed, and aortic rings about 2 to 3 mm long were made and suspended vertically in a 25 ml organ chamber filled with a control solution of pH 7.4. Some aortic rings were used as blood vessels in which endothelial cells were removed by rolling tweezers 7-8 times on paper towels. The lower part of the aortic ring was fixed in the organ chamber and the upper part was connected to a transducer coupler for recording the isometric growth force through the stirrup.

Phenylephrine ^10-6 M was added to the long-term chamber, and dimethylsulfoxide solution of ginsenoside Rg ₃ or Rg ₅ alone or methylene blue (MB) ^10-6 M or L- was added to the aortic ring showing stable contraction. Nitroarginine (L-NNA) was added together with ^10-6 M to observe vascular relaxation. Shrinkage by phenylephrine 10 ^-6 M was 100%, and the relaxation degree by ginsenoside Rg ₃ or Rg ₅ was expressed as% based on this.

2. Experimental Results

As shown in FIGS. 1 and 4, ginsenosides Rg ₃ and Rg ₅ relaxed concentration-dependently the blood vessels present in the endothelium, respectively. However, it showed no action on endothelial vessels and ginsenoside Rg ₃ by L-nitroarginine (L-NLA), an inhibitor of nitric oxide synthase, and methylene blue (MB), a soluble guanylate cyclase inhibitor. Alternatively, vascular relaxation of Rg ₅ was significantly inhibited.

From these results, ginsenosides Rg ₃ and Rg ₅ showed a vascular relaxation only in the vessels with endothelial cells. Therefore, ginsenosides Rg ₃ and Rg ₅ was found to be a safe medicinal component that does not show side effects such as hemolytic action and fish toxicity, unlike other saponin components that destroy even endothelial cells.

Experimental Example 2

[Vascular relaxation of processed saponin fraction]

1. Experiment Method

Vasorelaxiolation was measured in the same manner as in Experimental Example 1 with respect to the processed panaxadiol-based saponin fraction obtained in Example 7.

2. Experimental Results

As shown in FIG. 2, the processed panaxadiol-based saponin fraction relaxed concentration-dependently the hull tube in which the endothelium was present. However, it showed no effect on the endothelial vessels and vasorelaxation was significantly inhibited by L-nitroarginine, an inhibitor of nitric oxide synthase, and methylene blue, a soluble guanylate cyclase inhibitor.

From these results, it can be seen that the processed panaxanadiol fraction obtained in Example 7 exhibited vasorelaxation only in blood vessels with endothelial cells. Therefore, it was found that the processed panaxanadiol fraction is a safe pharmaceutical ingredient that does not exhibit side effects such as hemolysis or fish toxicity, unlike other saponin components that destroy even endothelial cells.

Experimental Example 3

[Cytotoxicity Test of Ginsenoside Rg ₃ ]

1. Experimental method:

HUVEC (human umbilical vein endothelial cells) cultured in M199 medium was suspended in physiological saline to a concentration of 20000 cells / 180 μl to make a cell suspension, and 180 μl per well was added to a 96-well plate and solvent dimethyl sulfoxide and 20 μl of Rg ₃ dissolved in dimethyl sulfoxide was added thereto, followed by incubation for 48 hours in a cell incubator at 37 ° C. and 5% carbon dioxide. Subsequently, 50 µl of 2 mg / ml of MTT [3- (4,5-dimethyl-thiazol-2'-yl) -2,5-diphenyltetrazolium bromide] solution dissolved in a phosphate buffer solution was added thereto, followed by the same conditions for 4 hours. After culturing under supernatant, the supernatant was removed, and 200 µl of dimethyl sulfoxide was added to measure absorbance at 540 nm, and the absorbance value was converted into cell number to inhibit cell growth by 50% in the case of solvent dimethyl sulfoxide and Rg ₃ . The IC ₅₀ value, a concentration, was determined and used as an indicator of cytotoxicity.

2. Experimental results:

In the case of dimethyl sulfoxide (control), it began to show cytotoxicity from 0.6% and showed dose-response by inhibiting 100% cell growth in 6%, IC ₅₀ was 18.4 μl / ml, and Rg ₃ was 1 to 100 In the concentration range of ㎍ / ㎖ showed the same pattern as dimethyl sulfoxide, IC ₅₀ was 26.7 ㎍ / ㎖, rather slightly placed value showed a tendency to be less cytotoxic. That is, the Rg ₃ administration group showed higher cell survival rate than the control group, and rather, had a cell growth promoting effect (FIG. 3).

Experimental Example 4

[Cytotoxicity Test of Ginsenoside Rg ₅ ]

1. Experimental method:

HUVEC (human umbilical vein endothelial cells) cultured in M199 medium was suspended in physiological saline to a concentration of 20000 cells / 180 μl to make a cell suspension, and 180 μl per well was added to a 96-well plate and purified water and purified water as solvents. 20 μl of lysed Rg ₅ was added, followed by incubation for 48 hours in a cell incubator at 37 ° C. and 5% carbon dioxide. Subsequently, 50 µl of MTT [3- (4,5dimethylthiazol-2'-yl) -2,5-diphenyltetrazolium bromide] solution (2 mg / ml) dissolved in ginseng salt buffer solution was added thereto, followed by the same conditions for 4 hours. After culturing under the supernatant, the supernatant was removed, and 200 µl of dimethyl sulfoxide was added, and the absorbance was measured at 540 nm.

2. Experimental results:

As shown in FIG. 5, the ginsenoside Rg ₅ administration group showed more active cell growth than the control group, although there was no statistical significance. Thus, ginsenoside Rg ₅ was found to be non-toxic to cells.

[Composition]

In the following, the Rg ₃ used as active ingredient is Rg _5, Rg ₃ and may be replaced by an Rg _5, fraction containing Rg ₃ can be replaced by a fraction containing Rg _5, Rg ₃ and Rg ₅ have.

[Composition Example 1]

100 g in total

According to the prescription described above, each component was uniformly mixed and then compression-molded in a tableting machine to prepare a tablet of 500 mg. This tablet contains 50 mg of the fraction obtained in Example 1. Adults take 3 to 10 tablets several times a day.

[Composition Example 2]

Crystalline cellulose, 10% hydroxypropyl cellulose ethanol solution and the fractions obtained in Example 5 were uniquely mixed and dried and pulverized using a granulator according to a conventional method, followed by carboxymethyl cellulose calcium and magnesium according to the above-described prescription. Stearates were mixed and compression molded in a tablet press to prepare 500 mg of tablets. This tablet contains 50 mg of the fraction obtained in Example 5. Adults take 3 to 10 tablets several times a day.

[Composition Example 3]

Rg ₃ obtained in Example 8 was dissolved in ethanol and soy phospholipid according to the prescription, and an injection was prepared by emulsifying by adding distilled water for injection and a solution of glycerin.

[Composition Example 4]

Pyridoxine Hydrochloride 300mg

1 g nicotinic acid amide

Calcium Pantothenate 1g

Riboflavin 200mg

30 g citric acid

20 g of fraction obtained in Example 1

Yin Yang Extract 200mg

Add water to make total 10ℓ.

Ingredients according to the above prescription To of It was dissolved in to prepare a liquid. 100 ml of this liquid contains 200 mg of the fraction obtained in Example 1.

[Composition Example 5]

According to the prescription described above, all the ingredients were uniformly mixed, assembled using a granulator according to a conventional method, and filled in a charger to prepare 500 mg of capsules per capsule. One capsule of this capsule contains 50 mg of Rg ₃ . Adults take 3 to 10 capsules several times a day.

Claims (6)

A vasodilator composition comprising ginsenosides Rg ₃ and / or Rg ₅ as active ingredients. The vasodilator composition according to claim 1, wherein the active ginsenosides Rg ₃ and / or Rg ₅ are pure Rg ₃ and / or Rg ₅ . The vasodilator composition according to claim 1, which is formulated in a unit dosage form with a pharmaceutically acceptable carrier. 4. The vasodilator composition according to claim 3, wherein the unit dosage form is a tablet, hard or soft capsule, granule, liquid, suspension, injectable solution or suspension. The vasodilator composition according to claim 4, wherein the unit dosage form is formulated to contain 10 to 500 mg of ginsenosides Rg ₃ and / or Rg ₅ . The vasodilator composition according to claim 1, wherein the active ginsenosides Rg ₃ and / or Rg ₅ are ginseng extracts containing at least 10% of Rg ₃ and / or Rg ₅ .